Sera Prognostics, Inc. Class A (SERA)

Sera Prognostics' stock price has been impacted by several events over the past six months. The Q3 2025 earnings report revealed that the company reported an EPS of -$0.16, beating forecasts, but revenue severely missed expectations at $16,000 versus an expected $150,000, causing the stock to drop by 6.73% to $3.12. The Q2 2025 earnings report showed revenue at $17,000, compared to $24,000 for the second quarter of 2024. Positive news regarding the PRIME study results led to a stock increase. The stock experienced a decrease of 14.81% from the prior week as of January 30, 2026, with a share price of $2.76. There was also a significant drop on February 6, 2026, where the share price started at $0.00 compared to a closing price of $2.32 the previous day. Insiders sold $156,296.00 in company stock in the three months leading up to February 8, 2026. Sera Prognostics unveiled a strategy to redefine pregnancy care in January 2026.

There is no explicit indication of demand seasonality for Sera Prognostics' products and services. Revenue fluctuations appear to be more closely tied to commercialization strategies, market adoption, progress in securing Medicaid coverage, and the timing of clinical study results rather than predictable seasonal patterns.

Sera Prognostics is a health diagnostics company focused on improving maternal and neonatal health through precision pregnancy care. The company discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products, with its primary product being the PreTRM® Test, which predicts the risk of spontaneous premature delivery. Sera Prognostics also has a pipeline of diagnostic tests for other pregnancy-related conditions and offers the LikeMine™ platform for pregnancy data comparisons.

Sera Prognostics' primary operations and sales are concentrated in the United States. The company plans to expand into the European market with regulatory submission anticipated in early 2026 and is engaging Medicaid plans in targeted U.S. states.

Sera Prognostics has maintained a "Moderate Buy" consensus rating from analysts, with an average rating score of 2.50. The company scored higher than 42% of companies evaluated by MarketBeat and ranked 661st out of 877 stocks in the medical sector. Positive PRIME trial results and the unveiling of a strategy to redefine pregnancy care have positively impacted its reputation. Insider stock sales could be perceived negatively by some investors.

Institutional Investors own approximately 6.94% of the company's stock. Insiders hold about 7.36% of the stock. Public Companies and Individual Investors collectively own approximately 85.70%. Another source indicates that 54.64% of the stock is held by institutions and 13.50% by insiders.